Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes

References

• Benson V, Marano MA. Current estimates from the National Health Interview Survey, 1995. Vital Health Statistics1998; 10: 1-428.
   Google Scholar
• Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. Journal of the American Medical Association 2004; 292: 1333-1440.
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. Journal of the American Medical Association 2003; 289: 179-186.
   PubMed Web of Science ®Google Scholar
• Dushoff J, Plotkin JB, Viboud C et al. Mortality due to influenza in the United States – an annualised regression approach using multiple-cause mortality data. American Journal of Epidemiology 2006; 163: 181-187.
   PubMed Web of Science ®Google Scholar
• Molinari NA, Ortega-Sanchez IR, Messonnier ML et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25: 5086-5096.
   PubMed Web of Science ®Google Scholar
• Wilschut JC, McElhany JE, Palache AM. Rapid Reference Influenza. Edinburgh: Elsevier-Mosby, 2006.
   Google Scholar
• Meier CR, Napalkov PN, Wegmuller Y, et al. Population-based study on incidence, risk factors, clinical complications, and drug utilisation associated with influenza in the United Kingdom. European Journal of Clinical Microbiology and Infectious Disease 2000; 19: 834-842.
   PubMed Web of Science ®Google Scholar
• Monto A, Napalkov P, Wegmuller Y. Medical resources utilisation for influenza and influenza-related complications in a large health insurance plan. 9th International Congress on Infectious Diseases 2000, Buenos Aires, Argentina: 15.
   Google Scholar
• Loughlin J, Poulios N, Napalkov P et al. A study of influenza and influenza-related complications among children in a large US health insurance plan database. Pharmacoeconomics 2003; 21: 273-283.
   PubMed Web of Science ®Google Scholar
• Committee on Infectious Diseases, American Academy of Pediatrics. Reduction of the influenza burden in children. Pediatrics 2003; 110: 1246-1252.
   Web of Science ®Google Scholar
• Barr CE, Schulman K, Iacuzio et al. Effect of oseltamivir on the risk of pneumonia and use of healthcare services in children with clinically diagnosed influenza. Current Medical Research and Opinion2007; 23: 523-531.
   PubMed Web of Science ®Google Scholar
• Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilisation in a working population. Occupational Medicine (London)1998; 48: 85-90.
   PubMed Web of Science ®Google Scholar
• Szucs T. The socio-economic burden of influenza. Journal of Antimicrobial Chemotherapy 1999; 44(Suppl B): 11-15.
   PubMed Web of Science ®Google Scholar
• Harper SA, Fukuda K, Uyeki TM et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports 2005; 54: 1-40.
   PubMedGoogle Scholar
• Nicholson KG, Aoki FY, Osterhaus AD et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355: 1845-1850.
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Hayden FG, Vrooman PS et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. Journal of the American Medical Association 2000; 283: 1016-1024.
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatric Infectious Disease Journal 2001; 20: 127-133.
   PubMed Web of Science ®Google Scholar
• Kaiser L, Wat C, Mills T et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalisations. Archives of Internal Medicine 2003; 163: 1667-1672.
   PubMed Web of Science ®Google Scholar
• Lynd LD, Goeree R, O'Brien B. Antiviral agents for influenza: a comparison of cost-effectiveness data. Pharmacoeconomics 2005; 23: 1083-1106.
   PubMed Web of Science ®Google Scholar
• Schmidt AC. Antiviral therapy for influenza: a clinical and economic comparative review. Drugs2004; 64(18): 2031-2046.
   PubMed Web of Science ®Google Scholar
• Watanabe A, Kobayashi M. Socioeconomic analysis of oseltamivir for influenza patients. Japanese Journal of Chemotherapy 2001; 49(2).
   Google Scholar
• Inoue T, Watanabe K, Chonabayashi N et al. Pharmacoeconomics of antiviral therapy for influenza in a Japanese hospital setting. Clinical Drug Investigation 2005; 25: 49-63.
   PubMed Web of Science ®Google Scholar
• Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 2002; 20: 2562-2578.
   PubMed Web of Science ®Google Scholar
• Smith, Roberts. Cost-effectiveness of newer treatment strategies for influenza. American Journal of Medicine 2002; 113(4): 300-307.
   PubMed Web of Science ®Google Scholar
• Lee PY, Matchar DB, Clements DA et al. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Annals of Internal Medicine 2002; 137: 225-231.
   PubMed Web of Science ®Google Scholar
• Postma MJ, Jansema, P, Scheijbeler H et al. Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults. Vaccine 2005: 23: 5365-5371.
   PubMed Web of Science ®Google Scholar
• Demicheli, Jefferson, Rivetti et al. Prevention and early treatment of influenza in healthy adults. Vaccine2000; 18: 957-1030.
   PubMed Web of Science ®Google Scholar
• Nichol KL. Cost–benefit analysis of a strategy to vaccinate healthy working adults against influenza. Archives of Internal Medicine 2001; 161: 749-759.
   PubMed Web of Science ®Google Scholar
• Armstrong EP, Khan ZM, Perry AS et al. The cost-effectiveness of zanamivir and oseltamivir for influenza treatment. Formulary 2000; 35: 979-988.
   Google Scholar
• Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Services Research 1988; 23: 203.
   PubMed Web of Science ®Google Scholar
• Poulios NS, Song J, Ackermann SP. Zanamivir vs oseltamivir: which drug is more cost-effective [letter]? Formulary 2001; 36: 383-384.
   Google Scholar
• Muennig PA, Khan K. Cost-effectiveness of vaccination versus treatment of influenza and antiviral treatment for healthy working adults. Clinical Infectious Diseases 2001; 33: 1879-1885.
   PubMed Web of Science ®Google Scholar
• Owens DK. Interpretation of cost-effectiveness analysis. Journal of General Internal Medicine 1998; 13: 716-717.
   PubMed Web of Science ®Google Scholar
• Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost effective analysis. American Journal of Medicine 2005; 118: 68-77.
   PubMed Web of Science ®Google Scholar
• Sander B, Gyldmark M, Hayden FG et al. Influenza treatment with neuraminidase inhibitors: cost-effectiveness and cost-utility in healthy adults in the United Kingdom. European Journal of Health Economics 2005; 50: 244-252.
   Google Scholar
• Vindt Holm M, Gyldmark M, Holme Hansen E. Pharmacoeconomic assessment of oseltamivir in treating influenza – the case of otherwise healthy Danish adolescents and adults. Pharmacy World & Science 2004; 26: 339-345.
   PubMedGoogle Scholar
• Järvinen A, Joutseno J, Gyldmark M. Cost effectiveness of oseltamivir for the treatment of influenza in adults, adolescents and children in Finland. Journal of Medical Economics 2007; 10: 199-214.
   Google Scholar
• Williams A. The measurement and valuation of health: a chronicle. Centre for Health Economics, University of York, UK. June 1995.
   Google Scholar
• Birch S, Gafni A. The ‘NICE’ Approach to Technology Assessment: an economics perspective. Health Care Management Science2004; 7: 35-41.
   PubMedGoogle Scholar
• O'Brien BJ, Goeree R, Blackhouse G et al. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada. Value in Health 2003: 6: 116-125.
   PubMed Web of Science ®Google Scholar
• Boivin G, Hardy I, Tellier G et al. Predicting influenza infections during epidemics with use of a clinical case definition. Clinical Infectious Disease 2000; 31: 1166-1169.
   PubMed Web of Science ®Google Scholar
• Reisinger K, Greene G, Aultman R et al. Effect of influenza treatment with oseltamivir on health outcome and costs in otherwise healthy children. Clinical Drug Investigation 2004; 24: 395-407.
   PubMed Web of Science ®Google Scholar
• Stouthard M, Essink-Bot M, Bonsel G et al. Disability weights for diseases in the Netherlands. Department of Public Health, Erasmus University, Rotterdam, the Netherlands, 1997.
   Google Scholar
• Rothberg MB, Fisher D, Kelly B et al. Management of influenza symptoms in healthy children: cost effectiveness of rapid testing and antiviral therapy. Archives of Pediatric Adolescent Medicine 2005; 159: 1055-1062.
   PubMed Web of Science ®Google Scholar
• Nettleman MD, White T, Lavoie S et al. School absenteeism, parental work loss, and acceptance of childhood influenza vaccination. American Journal of Medical Science 2001; 321: 178-180.
   PubMed Web of Science ®Google Scholar
• Rothberg MB, Bellantonio S, Rose DN. Management of influenza in adults older than 65 years of age: cost effectiveness of rapid testing and antiviral therapy. Annuals of Internal Medicine2003; 139: 321-329.
   PubMed Web of Science ®Google Scholar
• Postma MJ, Novak A, Scheijbeler HWKFH et al. Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza. Pharmacoeconomics2007; 597-509.
   Web of Science ®Google Scholar
• Van Genugten MLL, Heijnen M-LA, Jager JC. Pandemic influenza and healthcare demand in the Netherlands: a scenario analysis. Emerging Infections Diseases 2003; 9: 531-538.
   PubMed Web of Science ®Google Scholar
• Postma MJ, Bos JM, van Gennep M et al. Economic evaluation of influenza vaccination. Assessment for the Netherlands. Pharmacoeconomics 1999; 16(Suppl 11): 33-40.
   PubMed Web of Science ®Google Scholar
• Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Archives of Internal Medicine 1998; 158: 1769-1776.
   PubMed Web of Science ®Google Scholar
• Sander B, Gyldmark M, Aultman R et al. Impact on health outcome and costs of influenza treatment with oseltamivir in elderly and high-risk patients. Journal of Medical Economics 2004; 7: 67-83.
   Google Scholar
• Monto AS, Webster A, Keene O. Randomised, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. Journal of Antimicrobial Chemotherapy 1999; 44(Suppl B): 23-29.
   PubMed Web of Science ®Google Scholar
• Zambon M, Hays J, Webster A et al. Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. Archives of Internal Medicine2001; 161: 2116-2122.
   PubMedGoogle Scholar
• Jansen AG, Sanders EA, Hoes AW et al. Influenza- and respiratory syncytial virus-associated mortality and hospitalisations. European Respiratory Journal2007; 30: 1158-1166.
   PubMed Web of Science ®Google Scholar
• NICE. Guidance on the use of zanamivir, oseltamivir and amantadine for the treatment of influenza. Technology Appraisal No. 58; February 2003
   Google Scholar
• Turner D, Wailoo A, Nicholson K et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technology Assessment 2003; 7(35): 1-170.
   Google Scholar